DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06488027

Enrollment

200

Registered

2024-07-05

Start date

2023-05-05

Completion date

2023-11-27

Last updated

2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, Insomnia Disorder

Brief summary

Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the nervous system, among others. In this study we wanted to study the prevalence of DAO deficiency in pacients with insomnia symptoms.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Older than 18 years old * With one or more symptoms of insomnia * Explicit acceptance to participate to the study through informed consent

Exclusion criteria

* Insomnia symptoms that could be justified by the existance of another sleep pathology (e.g., narcolepsy)

Design outcomes

Primary

Measure	Time frame	Description
number of patients with insomnia symptoms and DAO deficiency	at the time of enrollment	number (absolute and percentage) of patients with insomnia symptoms and DAO deficiency

Countries

Spain

Outcome results